Skip to main content
. 2019 Jul 30;20:169. doi: 10.1186/s12931-019-1134-7

Fig. 3.

Fig. 3

Proportion of patients experiencing no clinically significant exacerbation. Mepolizumab 100 mg SC versus placebo. BMI body mass index, CI confidence interval, SC subcutaneous